SLC5A2 and atrial fibrillation: SGLT-2 inhibitors reduce atrial structural and electrical remodeling, including left atrial diameter and fibrosis, partly through inhibiting PGC-1a/NRF-1/Tfam pathways; and treatment with other SGLT-2 inhibitors has improved measures like atrial size, calcium handling, and epicardial fat volume that are linked to AF [76].